Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Ultimaster® - Drug eluting stent

  • ​Drug dose and delivery facilitate early vessel recovery
  • ​Gradient coating reduces risk of polymer cracking and delamination3
  • Ultimaster provides the optimal balance between stent strut coverage, radial force, and visibility
Read more Read less

​Stent Specifications

Stent designOpen cell
Stent materialCobalt Chromium L605
Strut thickness80 μm
​Cell size (for 3 mm stent)

​4.57 mm²

DrugSirolimus
Drug dose3.9 μg/mm stent length
PolymerPoly (DL-lactide-co-caprolactone)
CoatingAbluminal & gradient
Polymer degradation time and drug release3-4 months
 

Terumo's sponsorship is subject to all necessary regulatory approvals.

Drug dose and delivery facilitate early vessel recovery

  • ​Terumo's second-generation bioresorbable polymer coating (PDLLA /PCL) eliminates the long-term polymer exposure1
  •  Targeted abluminal drug delivery allows a reduced drug dose4
    • Half the amount required versus circumferential coating to deliver the same amount of drug to target tissue
    • Luminal side of the stent free from drug and polymer enhances endothelial coverage4

Gradient coating reduces risk of polymer cracking and delamination(3)

​​No drug polymer coating on parts of the stent that experience the most physical stress.5

Ultimaster provides the optimal balance between stent strut coverage, radial force, and visibility

  • ​Thick enough to:
    • Make the stent easy to see, for ease of deployment
    • Maintain radial force across the stent
  •  Thin enough to:
    • Maintain flexibility of the stent
    • Ensure stent coverage

The more complex the task, the more relevant the stent performance

  • Famous Terumo hydrophilic coating on delivery system, stent flexibility and smooth stent-balloon transition enable ultimate stent crossability
  • Low entry profile eliminates the gap between the tip and the guidewire for outstanding trackability

Designed towards facilitating the treatment of the most challenging bifurcations(6)

  • ​Open cell, 2-link design for easy side-branch access
  • Uniform architecture for optimal coverage of bifurcation anatomy

  • Gradient coating ensures polymer integrity reducing risk of delamination, even when overexpanded3

Side branch expansion

Test method: Expand a cell with a balloon at nominal pressure
Cell area: 14.5 mm²

Length (mm) ​Diameter (mm) ​ ​ ​ ​ ​
2.252.502.753.003.504.00
9DE-RD2209KSMDE-RD2509KSMDE-RD2709KSMDE-RD3009KSMDE-RD3509KSMDE-RD4009KSM
12DE-RD2212KSMDE-RD2512KSMDE-RD2712KSMDE-RD3012KSMDE-RD3512KSMDE-RD4012KSM
15DE-RD2215KSMDE-RD2515KSMDE-RD2715KSMDE-RD3015KSMDE-RD3515KSMDE-RD4015KSM
18DE-RD2218KSMDE-RD2518KSMDE-RD2718KSMDE-RD3018KSMDE-RD3518KSMDE-RD4018KSM
24DE-RD2224KSMDE-RD2524KSMDE-RD2724KSMDE-RD3024KSMDE-RD3524KSMDE-RD4024KSM
28DE-RD2228KSMDE-RD2528KSMDE-RD2728KSMDE-RD3028KSMDE-RD3528KSMDE-RD4028KSM
33DE-RD2233KSMDE-RD2533KSMDE-RD2733KSMDE-RD3033KSMDE-RD3533KSMDE-RD4033KSM
38DE-RD2238KSMDE-RD2538KSMDE-RD2738KSMDE-RD3038KSMDE-RD3538KSMDE-RD4038KSM

 

Recommended DES in ESC/EACTS 2014 guidelines.6

1 month DAPT. CE Mark approved for patients in need.2

 

 

Mastering Rapid and Healthy Vascular Repairhttps://www.terumo-europe.com/en-emea/clinicaldata/mastering-rapid-and-healthy-vascular-repairMastering Rapid and Healthy Vascular RepairPushing the boundaries of science and medical engineering for the improvement of health: Ultimaster combines an optimal balance between stent design for ultimate conformability with simultaneous polymer resorption and drug release, to match the procedure-triggered biological response in the vessel.(1) This results in optimal vessel recovery and potentially shortened DAPT time.(2)HayabusaArticlePage
CENTURY II Trial highlightshttps://www.terumo-europe.com/en-emea/clinicaldata/century-iiCENTURY II Trial highlightsMulticentre, intercontinental study - 58 sites in 13 countries across Europe, Japan, and South Korea - Primary endpoint: Freedom from TLF at 9 months - Secondary endpoint: rate of TVF; patient-oriented composite endpoint; rate of TLR, TVR, ST, cardiac death, MI; composite of cardiac death and MI; rate of bleeding and vascular complications - Clinical follow-up up to 5 years HayabusaArticlePage
DISCOVERY 1TO3 Trialhttps://www.terumo-europe.com/en-emea/clinicaldata/discovery-1to3-trialDISCOVERY 1TO3 Trial60 MVD patients with OFDI, single arm, primary endpoint TLF @ 12M. Ongoing.HayabusaArticlePage

 

 

 

 

 

 

​1 Data on file at Terumo Corporation (Doc nr. BioRes02-T).
2 Ultimaster IFU. 1 month DAPT CE Mark approved for patients in need. Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month.
3 ​Comparing to DES with uniform coating. Saito N. et al. Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating. Medical Devices: Evidence and Research 2016:9.
4 Virmani R. CvPath Rabbit Iliac artery. Barbato E. Presented at EuroPCR 2013.
5 Data on file at Terumo Corporation (Doc nr. Grad01-T).
6 Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Inter v. 2015 Aug 13. doi: 10.1002/ccd.26150.
7 ​Windecker S et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619.

Did you not find the product you were looking for?